Patient Guide: A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 289 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05100862
Status: 🟢 Enrolling Now
Condition: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Phase: PHASE3

Where You Can Participate

This study is available at 289 locations across the country.

Top locations include:
  • • Fresno, California
  • • Irvine, California
  • • Los Alamitos, California
  • • And 286 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma - Join Clinical Trial NCTNCT05100862

How to Join This Clinical Trial - NCTNCT05100862

Learn how to participate in this PHASE3 trial studying an investigational therapy for Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT05100862 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 289 locations. Find a study site near you:

Clinical Research Site

Fresno, California 93730-3595 - United States

Status: RECRUITING

Clinical Research Site

Irvine, California 92618-3734 - United States

Status: RECRUITING

Clinical Research Site

Los Alamitos, California 90720-3302 - United States

Status: RECRUITING

Clinical Research Site

Los Angeles, California 90017-4803 - United States

Status: RECRUITING

Clinical Research Site

Los Angeles, California 90067-2011 - United States

Status: RECRUITING

Clinical Research Site

Los Angeles, California 90095-3075 - United States

Status: RECRUITING

Clinical Research Site

San Diego, California 92103-2106 - United States

Status: RECRUITING

Clinical Research Site

San Diego, California 92123-2701 - United States

Status: RECRUITING

Clinical Research Site

Jacksonville, Florida 32207-8432 - United States

Status: RECRUITING

Clinical Research Site

Pembroke Pines, Florida 33026-4119 - United States

Status: RECRUITING

And 279 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships